Dr. Romm is currently a senior executive at Takeda Oncology leading medical affairs. She started her Pharmaceutical Industry career in 1997 at Roche. Since then, she moved to clinical research and helped conducting Phase III/IV studies and IITs. She held multiple positions in Medical Affairs, including US Medical Director for European Biotech firms (Octapharma, BPL/DCI Biologics), field Medical positions at Global Pharma Companies (Novartis, Roche), small biotechs (Ipsen) and mid-size firms (Solvay, Allergan, Takeda). Julia developed Medical Affairs/ Med Communication strategy for US launches of several products in Hematology/ Oncology: IVIG in ITP, Proteasome Inhibitors in Multiple myeloma, TKI in CML/ALL, targeted therapy in AML, moAb in GVHD prophylaxis.

Julia has extensive experience collaborating with Academic Institutions/ Hematology/Oncology KOL relationships in the NorthEast and West spanning 20+ years. She collaborates with BD, R&D, Clinical development, Value/Access, Marketing, Sales and is a molecule lead for I/O pipeline.

Julia Romm received a Ph.D in Public Health at the Institute of Public Health of the Russian Federation, in Moscow, Russia. Julia holds a BSN (CA State University) with emphasis in Public Health and holds a PH Certificate as well as OCN Certificate. She practiced Nursing at UCLA Medical Center. She also holds a MBA from Pepperdine University. Julia is ASCO, AACR and ASH member. Julia is fluent in Russian and French and enjoys traveling with her family.